Laser Treatment for Onychomycosis in Diabetes

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2015 by BCDiabetes.Ca
BritaMed, Inc.
Information provided by (Responsible Party):
BCDiabetes.Ca Identifier:
First received: December 16, 2013
Last updated: July 27, 2015
Last verified: July 2015
Fungal infections of the toe affect one in three people with diabetes. Current treatments for fungal toe infections include oral medications, but these drugs often interact with other common medications. We are studying a new treatment for fungal toe infections involving the use of a laser device. We will compare to the standard treatment which is a type of antifungal medication. This laser has been tested in small numbers of patients with minimal side effects. There will be 60 participants selected for our study, of which 30 will receive standard treatment and the rest will receive laser treatment.

Condition Intervention
Diabetes Mellitus, Type 2
Device: Laser Treatment YAG laser
Drug: Standard Treatment (control group) terbinafine hydrochloride tablets

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluating the Effectiveness of Laser Treatment for Onychomycosis of the Hallux in Patients With Diabetes: A Randomized Controlled Trial

Resource links provided by NLM:

Further study details as provided by BCDiabetes.Ca:

Primary Outcome Measures:
  • Microbiological Cure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    One primary outcome will be the proportion of participants with microbiological cure (by KOH and culture) by 6 months post-randomization (i.e.: initiation of treatment).

  • Side effects from laser treatment [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

    Other primary outcomes include safety outcomes. Specifically, safety outcomes of interest will include the side effects listed below:

    • Usual side effect:

      o Feeling of warmth, heat, or tingling at the laser target site (only during treatment)

    • Rare side effects:

      • Discoloration/burn marks on surface of the nail
      • Slight or mild pain (only during treatment)
      • Redness of the treated skin around the nail (lasting 24-72 hours)
    • Rare laser effect:

      o Sometimes the laser creates 'sparks' on the surface of the nail - this does not cause any problems

    • Extremely rare laser effects:

      • Blistering of the treated skin around the nail
      • Scarring of the treated skin around the nail

Secondary Outcome Measures:
  • Clinical cure by visual assessment [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Secondary outcomes will include the proportion of participants experiencing clinical cure by visual assessment (planimetry and photograph) will be evaluated.

  • Quality of Life [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    The other secondary outcome will be improvement in quality of life as measured by the validated "NailQoL" questionnaire which assesses symptom, emotion, and functional domains.38

Estimated Enrollment: 60
Study Start Date: January 2016
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Laser Treatment
Participants randomized to laser group will undergo laser treatment at baseline and be asked to return for 2 subsequent visits six weeks apart (at weeks 6 and 12) to undergo further laser treatment of the hallux. Each visit will last approximately 45 minutes. Laser energy (1064 nm Nd:YAG) will be delivered via an optical fibre (300 μm core/320 μm clad) secured in a hand piece. Laser energy will be delivered by maintaining the tip of the optical fibre 3 mm from the treatment area to achieve around 1-1.5 mm diameter spot size (25.5 J/cm2 fluence per pulse; 10-pulse pulse-train to each spot in 0.5 seconds). Multiple treatment spots will be delivered to cover the entire area of involvement.
Device: Laser Treatment YAG laser
Other Names:
  • 1064 nm Nd:YAG laser
  • FOX laser
Active Comparator: Standard Treatment (control group)
Control group volunteers will be asked to dedicate the same amount of time to the project with the same number of visits. However, they will receive conventional terbinafine therapy instead of laser treatments. Therefore, each of the 3 treatment visits would last only about 20 minutes.
Drug: Standard Treatment (control group) terbinafine hydrochloride tablets
Other Name: terbinafine hydrochloride tablets


Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Provides full informed consent to participate in the study;
  • At least 19 years of age;
  • Established diagnosis of diabetes mellitus at the time of screening for the study according to Canadian Diabetes Association (CDA) criteria;
  • Clinically assessed to have subungual onychomycosis (fungal infection of the nail) of the hallux, confirmed by KOH and culture performed at the screening visit.

Exclusion Criteria:

  • Presence of necrotizing fasciitis, cellulitis, wet gangrene, gas gangrene, erythema gangrenosum, or psoriasis;
  • Presence of peripheral arterial disease defined as an ankle-brachial index less than 0.6 on either lower extremity;
  • Presence of peripheral neuropathy defined as a biothesiometry score of less than 20 volts on either lower extremity;
  • Treatment with oral terbinafine (Lamisil), itraconazole (Sporanox), or griseofulvin within 12 months of the proposed study start date;
  • Treatment with any topical antifungal medications including ciclopirox, itraconazole, or other over-the-counter remedies for toenail infection within 1 month of randomization;
  • Female of childbearing potential who does not agree to practice sexual abstinence or use a medically acceptable method of contraception for the duration of the study and for at least 1 month (30 days) after the last day of test article administration; (A woman of childbearing potential is one who is biologically capable of becoming pregnant; this includes women who are using contraceptives or those women whose sexual partners are either considered sterile or using contraceptives.)
  • Has a physical disability or psychiatric diagnosis which would limit the ability to adhere to the study regimen, as judged by the Investigator;
  • Is a prisoner, or is in pre-trial;
  • Is known to be without a fixed address;
  • Has documented evidence of a history (e.g. liver testing) of substance abuse within the 12 months prior to screening for study entry;
  • Is a Workers Compensation Board (WCB) patient;
  • Is unable to easily communicate in oral and written English.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02019446

Contact: Thomas G Elliott, MBBS (604) 875-5900

Canada, British Columbia
Diamond Centre Not yet recruiting
Vancouver, British Columbia, Canada, V5Z 1M9
Contact: Thomas G Elliott, MBBS    (604) 875-5900   
Principal Investigator: Thomas G Elliott, MBBS         
Sponsors and Collaborators
BritaMed, Inc.
Principal Investigator: Thomas G Elliott, MBBS University of British Columbia
  More Information

Responsible Party: BCDiabetes.Ca Identifier: NCT02019446     History of Changes
Other Study ID Numbers: H13-03369
Study First Received: December 16, 2013
Last Updated: July 27, 2015
Health Authority: Canada: Health Canada

Keywords provided by BCDiabetes.Ca:
type 2 diabetes mellitus
laser treatment

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Nail Diseases
Skin Diseases
Skin Diseases, Infectious
Anti-Infective Agents
Antifungal Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2015